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Background: Recent studies have shown that a selective group of patients with primary cystic neoplasms
of the pancreas can be managed conservatively by radiological follow-up. The aim of this study was to
analyze if such a strategy is efﬁcient and safe.
Patients and methods: A retrospective analyses was performed of patients who underwent resection
between January 1992 and January 2006 for primary cystic neoplasms of the pancreas in an era of
aggressive management (i.e. all patients underwent resection) in order to analyze if the selective algo-
rithm as proposed by the Memorial Sloan-Kettering Cancer Center is efﬁcient and safe.
Results: One hundred patients underwent a resection for pancreatic cysts. Thirty-ﬁve percent of the
patients with symptomatic cysts had a (pre)malignant lesion compared with 15% of the patients with an
incidental cysts. In hospital mortality occurred in 1% of the patients and a postoperative complications in
39%. The Memorial Sloan-Kettering Cancer Center nomogram was able to correctly identify all patients
with a benign incidental cyst.
Conclusion: A selective management strategy can be implemented and algorithm proposed by the
Memorial Sloan-Kettering Cancer Center nomogram is safe and efﬁcient.
 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Surgeons are increasingly being asked for the surgical manage-
ment of patients with cystic neoplasms.1 Most cystic lesions of the
pancreas are benign and only aminority require resection. Computed
tomography is the imagingmodalityof choice forpancreaticneoplasm
including primary cystic neoplasms and regional guidelines were
established since 1997.2
Primary cystic neoplasms of the pancreas consist of several
pathological entities which include serous cystic neoplasms (SCNs),
mucinous cystic neoplasms (MCNs), intra-ductal papillary mucinous
neoplasm (IPMNs), solid pseudopapillary neoplasms (SPNs) and
various other extremely rare cystic neoplasms (i.e. cystic islet cell
neoplasms, teratomas, lympho-epithelial neoplasms).
Serous cystic neoplasms are cysts which are lined by serous cells
and are considered to be uniformly benign except for a few re-
ported cases.3 Mucinous cystic neoplasms are potentially malig-
nant and IPMNs of the pancreas should also be considered of
malignant potential. Finally, solid pseudopapillary neoplasms of the: þ31 20 691 48 58.
).
ciates Ltd. Published by Elsevier Ltpancreas are rare neoplasms that predominate in women. This
neoplasm is unique because, although it has a histologically
malignant appearance, its biologic behavior is usually much less
virulent.4
The appropriate management of primary cystic lesions is contro-
versial. In the past most authors recommended an aggressive
management strategy because of the unknown natural history and
the diagnostic uncertainty of these pancreatic cysts.5 Several recent
reports have recommended a more selective approach toward
primary pancreatic neoplasms because improved radiological
imagingallows the identiﬁcationof groupsofpatientswith lowriskof
malignancy.6e8 The aim of the present study was to analyze if
a selective approachwould have been safe and efﬁcientwhenapplied
to a cohort of aggressively managed patients.2. Patients and methods
Patients who underwent pancreatic resection between January
1992 and January 2006 from our prospective database were
selected. During this time-frame our hospital enforced an aggres-
sive management approach and offered a resection to all patients
with a primary cystic neoplasms which were referred to us. This
policy was used because of the limited evidence in the literatured. All rights reserved.
Table 1
General characteristics.
(n ¼ 100)
Gender
Male/female 23/77
Median age (range) 56 (13e84)
Symptoms
Pain 66
Weight loss 30
Nausea 19
Vomiting 10
Jaundice 12
No. of patients with a history
of chronic pancreatitis
13
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modalities and regarding a wait-and-see approach. Procedures
included (pylorus preserving) pancreatoduodenectomy (n ¼ 603),
and total or left pancreatectomy (n ¼ 129). Beger and Frey proce-
dures were excluded. All consecutive patients with pathologically
proven primary cystic neoplasms of the pancreas formed the study
group. In order to analyze whether or not the resection rate has
increased, patients with primary cystic neoplasms were compared
with the patients who underwent resection for all other solid
pancreatic neoplasms throughout the years.
The diagnostic work-up used for pancreatic neoplasms generally
consisted of orienting ultrasound (US) followed by computed
tomography (CT).2 Endoscopic retrograde cholangiopancreaticog-
raphy (ERCP) is generally performed in jaundiced patients to alle-
viate symptoms. Endoscopic ultrasonography (EUS) is performed
when no tumor is found on CT scan or when there is doubt between
a pseudocysts or primary pancreatic neoplasm. A EUS guided
aspiration with ﬂuid analysis is generally not preformed. Finally,
diagnostic laparoscopy (DL) was routinely performed in the earlier
years as ﬁnal step in staging as part of a longitudinal study. Serum
tumor markers were seldom used and not analyzed in the present
study. The ﬁndings were discussed in a multidisciplinary team and
patients were generally classiﬁed as having a benign cyst, a (pre)
malignant cyst or indeterminate.
The patient records were used to collect demographic, clinical,
operative and pathological data. The preoperative data included
age at presentation, sex, symptoms, imaging and clinical diagnosis.
The surgical parameters analyzed included the location of the
neoplasm and the type of procedure performed, the postoperative
complications and hospital stay. The deﬁnitions of complications
used for the present study have been reported previously.9,10 In
short, pancreatic ﬁstula was deﬁned as abdominal drain ﬂuid with
amylase levels three times the normal serum levels. Delayed gastric
emptying was deﬁned as either the need for nasogastric intubation
for 10 days or more or the inability to tolerate regular food before or
on the 14th postoperative day. In-hospital mortality was deﬁned as
death during hospital stay including death during re-admittance
within 30 days after discharge.
The histopathological data analyzed comprised the size of the
neoplasm, histological features suggestive of malignancy and status
of the resection margins. Tumors were considered malignant in
case of in situ or invasive malignancy. Al resection specimens were
reexamined and classiﬁed according to the recent WHO criteria.11
The follow-up data was recorded through review of the hospital
records, the outpatient visits and telephonic interview.
The present study retrospectively applied the algorithm (Fig. 1)
proposed by the Memorial Sloan-Kettering Cancer CenterSolid component
Yes No
Resection Size < 3.0 cm
Yes
Rad. follow-up No
Age< 65 yrs
Yes
Resection No
Symptomatic cyst
Resection
Incidental cyst
Rad. follow-up
Fig. 1. Decision tree as adapted from Memorial Sloan-Kettering Cancer Center.7(MSKCC)7 in order to analyze if a selective management strategy
could have been implemented in the patients who underwent an
aggressive management strategy which was enforced during the
study period. This aggressive approach was enforced by all
surgeons because of the limited evidence at the time for a selec-
tive management strategy. We cross-referenced the operative
database with the to ensure that the aggressive approach was
implemented.
Data analyses were performed using SPSS software (SPSS,
Chicago, Illinois, USA). A p value of less than 0.05 was considered
statistically signiﬁcant. Correlation analysis was performed using
the Pearson’s correlation coefﬁcient or the Spearman’s correlation
coefﬁcient depending on the data distribution. Univariate analysis
was performed using Pearson’s c2 test to determine which vari-
ables were statistically signiﬁcant. Fisher’s exact test was used
when a table had a cell with an expected frequency of less than ﬁve.
For continuous data the unpaired t-test and the ManneWhitney
test were used were appropriate.3. Results
One thousand and thirty-ﬁve patients presented with a poten-
tially resectable pancreatic neoplasm. Eight hundred patients
underwent surgery. One hundred out of 732 patients (13.7%)
underwent a resection for pancreatic neoplasms for a pathologi-
cally proven primary neoplasm of the pancreas and formed the
study group (Table 1). The remaining patients (n ¼ 632) had other
malignant or benign neoplasms or underwent drainage of a pseu-
docyst (n ¼ 68). These patients were excluded from further anal-
ysis. One hundred and eighteen patient underwent transgastric
endoscopic drainage and 118 patients were managed conserva-
tively in an outpatient follow-up setting. These patients were also
excluded from further analysis.3.1. Diagnostic work-up
After discussion in a multidisciplinary team in a majority of
patients there was agreement that a cyst was present but it was
uncertain whether the cyst was serous or mucinous.3.2. Perioperative parameters
One patient in the overall cohort died (Table 2). This patient
underwent a pancreatoduodenectomy and died due to uncontrol-
lable delayed massive hemorrhage after unsuccessful coiling of the
gastroduodenal artery and eventually had a SCN after pathological
evaluation.
Table 4
The association between cysts <3 cm and malignancy.
Malignant
(n ¼ 30)
Benign
(n ¼ 70)
p
Preoperative no. of patients
with cyst <3 cm on CT
8 (27) 26 (37) 0.311a
No. of patients with a solid
component in cyst
8 (27) 10 (14) 0.162a
No. of patients remaining
after excluding those
with a solid component on CT
0 16 (23) 0.002b
Numbers between parentheses are percentages.
a c2.
b Fisher’s exact test.
Table 2
Perioperative parameters.
(n ¼ 100)
Surgical procedures
Distal pancreatectomy 39
Pylorus-preserving
pancreatoduodenectomy
41
Resection of uncinate process 1
Kausch-Whipple Procedure 7
Total pancreatectomy 6
Central pancreatectomy 6
Previous cystogastrostomy 2
Median operative time (range) 3 h 52 min
(40 mine9 h 48 min)
Splenectomya 33/51 (65)
Complications (overall) 39
Surgical 27
Pancreaticojejunostomy leakage 4
Hepaticojejunostomy leakage 2
Bleeding 4
Abscess 6
Wound infection 2
Delayed gastric emptying 6
Other 9
Systemic 15
Pulmonal 9
Renal 6
No. patient who underwent relaparotomy 6
Median postoperative hospital stay (range) 13 days (5e111)
Hospital mortality 1
a Analysis of patients who underwent distal pancreatectomy, total pancreatec-
tomy and central pancreatectomy.
S.M.M. de Castro et al. / International Journal of Surgery 9 (2011) 655e658 657
ORIGINAL RESEARCH3.3. Pathology & follow-up
Most patient had a SCN (n ¼ 32) follow by MCN (n ¼ 30), IPMN
(n ¼ 26) and SPN (n ¼ 12) (Table 3). The mean follow-up was 45
months and ranged from 27 months to 173 months.3.4. Evaluation of a selective management strategy
Analysis of symptomatic versus incidental cysts found that the
size of the cyst was comparable in these groups (Table 4). Overall 22
patients had SCN with symptoms and 10 patients without symp-
toms. Four patients with an incidental cyst turned out to have frank
malignant disease at pathology consisting of IMPN (n¼ 3) andMCN
(n ¼ 1). The number of patients with a cyst smaller than 3 cm was
also comparable between these patients. Overall, 34 patients had
a cyst smaller than 3 cm and 8 of these hadmalignant disease. Eight
of these patients with malignant disease had a solid component on
CT and were excluded according the algorithm as proposed by theTable 3
Pathology.
(n ¼ 100)
Serous Cystic Neoplasm 32
Mucinous Cystic Neoplasms 30
Benign 14
Malignant 16
Intra-ductal Papillary Mucinous Neoplasm 26
Benign 15
Borderline 2
Malignant 9
Solid Pseudopapillary Neoplasm 12
Median neoplasm size in centimeters (range)a 5.0 (1.1e25)
R0 resection 81
Numbers between parentheses are percentages unless indicated otherwise.
a Size consists of longest axis. Tumors are classiﬁes according to the WHO
histopathological classiﬁcation.MSKCC. Thus, using the algorithm proposed by the MSKCC, none of
the 100 patients with a malignant cyst and would have been
managed conservatively by radiological follow-up.
4. Discussion
The present study shows that a conservative management
strategy by radiological follow-up is feasible in selected patients
using the algorithm proposed by the MSKCC. In this algorithm
patients with small asymptomatic cystic neoplasms smaller than
3 cm with no solid component can be monitored safely with
virtually no risk of malignancy.
Pancreatic SCNs have virtually no malignant potential and there
are only ten reports in literature of malignant SCNs.3 If asymptom-
atic, they can almost certainly be observed safely, especially when
they occur in the head of the pancreas in an older individual who
would otherwise require a pancreaticoduodenectomy.12 However,
this strategy has not been thoroughly evaluated. If symptomatic,
most patients require resection since most symptomatic lesions will
not be amenable to “simple” enucleation because this procedure is
associated with a relatively high morbidity and mortality rate
compared to resection.12
The vast majority of MCNs are not true invasive adenocarcinoma
but mucinous cystadenomas that may harbor carcinoma-in-situ.
The time course of progression from benign to malignant has not
been clearly determined. If resected these patients are all potentially
cured. In contrast, malignant MCNs with an invasive component
behave very similar to ductal adenocarcinoma. Although the older
literature suggested that malignant MCNs are less malignant than
other pancreatic cancers, these reports probably included those
MCNs with only dysplasia or PanIN type lesions, thus biasing the
survival of true malignant MCNs.13
The 5-year survival rate after resection for MCNs varies from 15%
to 70% in the literatures.13,14 Survival disparity in MCNs was
attributed to difﬁculties and differences in the histopathologic
classiﬁcation of these mucinous cystic tumors.3 The frequency of
malignant transformation of branch duct IPMNs ranges from 6% to
46% while that of main duct IPMN is approximately 60%.15e17 The
overall 5-year survival rate of IPMNs is approximately 40e60% with
no signiﬁcant difference between main duct and branch duct.18,19
Fernández-del Castillo et al.20 recently proposed an algorithm
for the management of incidental cysts. In this algorithm the
authors advise a wait-and-see strategy for incidental cysts smaller
than or equal to 2 cm based on the fact that 4% of these cyst are
malignant. However the authors also pointed out that up to 50% of
these patients had premalignant disease including IPMNs and
MCNs. A study by Walsh et al.8 prospectively observed all patients
with an asymptomatic cyst and a negative cyst aspirate deﬁned as
having no mucin and CEA < 200 U/L in the aspirate. The authors
found that a nonoperative treatment strategy was more often
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present study used the algorithm from the MSKCC since this study
is the largest to date which analyses the safety and efﬁcacy of
a selective approach for primary cystic neoplasms of the pancreas.
Onemajor drawback of the study is the fact that follow-upwas only
2 years. These tumors are generally slow growing and it can take
decades to develop frankmalignancy so the safety of the decision to
observe has yet to be proven. Another drawback is the fact that the
algorithm was created on a large series of patients, most of which
did not undergo resection, and therefore include many cysts that
were undiagnosed and probably were not neoplastic.
One drawback of the present study is that only patients with
proven primary cystic neoplasms were included. Patients with an
asymptomatic benign pancreatic cysts (e.g. small pseudocysts)
were not included. Therefore the study does not have the true
denominator of pancreatic cysts. On the other hand the present
study does thoroughly test the MSKCC algorithm is by solely
including patients with proven primary neoplastic cysts since most
of the patients in the MSKCC algorithm did not undergo resection
and therefore also include many cysts that were undiagnosed and
probably not neoplastic. The present study found that no patient
with a malignancy would have been missed when applied to
patient with a proven primary pancreatic cyst.
The algorithm could possible improve if more IPMN character-
istics were included in the decision tree such as guidelines
proposed by the International Association of Pancreatology (IAP).21
The IAP guideline for the management of IPMN proposes that
neoplasm < 3 cmwith high-risk stigmata including mural nodules,
dilated main duct and positive cytology should undergo resection.
Otherwise it is safe towait and see in these small neoplasms. This is
conﬁrmed by a recent study by Salvia et al.22 consisting of 109
patients with branch duct IPMN showed that surgery is indicated in
only 20% of these patients. Risk factors for malignancy includemain
duct diameter of >3.5 cm, the presence of mural nodules and
a thick wall, a CA 19.9 > 25 U/L and the presence of any symptom
including recent onset diabetes. The remaining 80% of the patients
underwent radiological follow-up but again the follow-up was
limited in this study.
In conclusion, the present study shows that a selective approach
is appropriate in balancing the risk of malignancy with the risk of
mortality. Intensive follow-up is important since the safety of such
a selective management strategy has not yet been proven. The IAP
recommends that radiological follow-up by means of MRI or thin
slice CT should occur at every 6e12months for neoplasms between
1 and 2 cm and every 3e6 months for neoplasms between 2 and
3 cm. The interval of follow-up can be lengthened after 2 years of no
change.
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